摘要
目的:观察法舒地尔对急性冠脉综合征(ACS)患者外周血MCP-1、hs-CRP和MMP-2水平的影响,探讨Rho激酶抑制剂对ACS患者斑块的稳定作用。方法:选择未行介入治疗的ACS患者82例,稳定型心绞痛(SAP)患者20例及正常对照组20例。ACS患者随机分为常规治疗组和法舒地尔治疗组,治疗14 d,比较各组及ACS患者治疗前、后外周血MCP-1、hsCRP和MMP-2水平的差异。结果:ACS组患者MCP-1、hs-CRP及MMP-2水平明显高于SAP组及正常对照组(P<0.01);ACS患者治疗14 d后,同常规治疗组相比,法舒地尔组MCP-1、hs-CRP及MMP-2水平显著降低(P<0.01)。结论:法舒地尔能够降低ACS患者血MCP-1、hs-CRP及MMP-2水平,发挥稳定粥样斑块的作用。
Objective ：To investigate the effects of fasudil on MCP- 1, hs -CRP and MMP- 2 in patients with acute coronary syndrome （ACS） and to elucidate the plaque stability effect of Rho - kinase inhibitor on ACS. Methods：Twenty patients with stable angina peetoris （SAP） were selected as SAP group and 20 healthy people were selected as control group. Eighty - two patients with ACS without undergoing intervention therapy were random- ly divided into conventional therapy group and fasudil treatment group. The peripheral blood levels of MCP - 1, hs - CRP and MMP -2 were evaluated at pre and post treatment. Results：The peripheral blood levels of MCP - 1, hs - CRP and MMP - 2 were significantly higher in ACS group than that of SAP group and normal control group. After 14 days treatment, the levels of MCP - 1, hs - CRP and MMP - 2 were declined in the two ACS groups, while the parameters in fasudil treatment group were significantly lower than that of conventional therapy group （P 〈 0.01 ）. Conclusion： Fasudil can inhibit inflammatory response and extracellular matrix degradation of the coronary plaque to some extent, thus play an important role in plaque stability in patients with ACS.
出处
《西北国防医学杂志》
CAS
2013年第5期424-426,共3页
Medical Journal of National Defending Forces in Northwest China
